Eplerenone
Eplerenone has been studied in 16 papers since 2020: 3 trials and 6 observational studies in people, 3 in animals, 4 reviews; 13 in the past year. It is an approved medicine. The newest paper, Nov 9, 2026: “Clinical outcomes associated with angiotensin receptor–neprilysin inhibitors versus mineralocorticoid receptor antagonist initiation in patients with hypertension without heart failure: a propensity score–matched…”.
11 new papers in 30 daysSee all 22 papers on eplerenone
At a glance
The findings reach people, from one lab or study. 4 independent labs in 5 countries; 60 trials, 1 about aging, 18 with no results posted.
“Similarly, median change in eGFR was 0.0 mL/min/1.73m2 in both groups (p=0.71).”
None of its findings points the other way.
- 4 independent labs in 5 countries
- 60 trials, 1 about aging, 18 with no results posted
- Funders: National Heart, Lung, and Blood Institute and 2 more
- Human trial3
- Humans6
- Animals3
Studies in people
2 studies gave eplerenone to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on renal functionMedian eGFR change 0.0 mL/min/1.73m2 in both groups (p=0.71); median serum creatinine change 0.00 mg/dL in both groups (p=0.70) no change: Has no effect on hyperkalemia1.2% versus 1.3% (p=1.00) | Randomized trial6 months | 162 peopleBoth30–75 yearsMidlife adults; Older adults; Obesity and essential hypertension | ESC Congress 2026 abstract, Oct 26, 2026 |
up: Improves blood pressure control63.3% vs. 36.7%, p = 0.04 | Randomized trial6 months | 60 peopleBoth58.4 yearsMidlife adults; stroke survivors with uncontrolled resistant hypertension | Equity neuroscience, Oct 16, 2025 |
What did studies of eplerenone find?
6Studies of eplerenone measured 6 outcomes, among them pyridinoline and (iso)desmosine, lifespan and aortic aneurysm.
Pyridinoline and (iso)desmosine
upin mice1
1 study
Pyridinoline and (iso)desmosine
upin mice1
Eplerenone increases pyridinoline and (iso)desmosine in mice (Tgfb1L/L mice).
AnimalsTgfb1L/L miceaorta
Lifespan
upin mice1
1 study
Lifespan
upin mice1
Eplerenone extends lifespan in mice (Tgfb1L/L mice).
AnimalsTgfb1L/L micechronic
Aortic aneurysm
downin mice1
1 study
Aortic aneurysm
downin mice1
Eplerenone prevents aortic aneurysm in mice (Tgfb1L/L mice).
AnimalsTgfb1L/L miceaortachronic
Hyperkalemia
no changein humans1
1 study
Hyperkalemia
no changein humans1
Eplerenone showed no clear effect on hyperkalemia in humans (Obesity and essential hypertension; compared with irbesartan-based treatment) (1.2% versus 1.3% (p=1.00)).
Human trialObesity and essential hypertension; compared with irbesartan-based treatment25 mg twice daily6 monthsn = 162
Renal function
no changein humans1
1 study
Renal function
no changein humans1
Eplerenone showed no clear effect on renal function in humans (Obesity and essential hypertension; compared with irbesartan-based treatment) (Median eGFR change 0.0 mL/min/1.73m2 in both groups (p=0.71); median serum creatinine change 0.00 mg/dL in both groups (p=0.70)).
Human trialObesity and essential hypertension; compared with irbesartan-based treatment25 mg twice daily6 monthsn = 162
Blood pressure control
upin humans1
1 study
Blood pressure control
upin humans1
Eplerenone improves blood pressure control in humans (stroke survivors with uncontrolled resistant hypertension) (63.3% vs. 36.7%, p = 0.04).
Human trialstroke survivors with uncontrolled resistant hypertension6 monthsn = 60
What is eplerenone linked with?
1Studies link eplerenone with composite adverse cardiovascular events.
Composite adverse cardiovascular events
downin humans1HR 0.75
1 study
Composite adverse cardiovascular events
downin humans1HR 0.75
Eplerenone lowers the risk of composite adverse cardiovascular events in humans (HR: 0.75, 95% CI: 0.64–0.88).
Review4–44 monthsn = 54,964
Has eplerenone been tested in people?
1 of 60 about agingYes: 3 trials and 6 observational studies in people have been published, and 59 trials are registered.
About aging
A study to compare heart failure medicines in one combined pill with usual care.
Phase 3Not yet recruiting
Approved
Sep 27, 2002Heart Failure, Hypertension, Myocardial Infarction, Myocardial Infarction, Acute, heart failure with reduced ejection fraction, high blood pressure, symptomatic heart failure
Repurposing
Phase 4Results posted1 trial
Phase 3Completed1 trial
Phase 4Results posted1 trial
Phase 4Results posted3 trials
Phase 4Completed1 trial
Heart failure with preserved ejection fraction
Phase 4Terminated1 trial
All 36Fewer
Every condition in trials
Pharmacodynamic
Phase 4Completed2 trials
Readouts due
- Feb 10, 2027
- Oct 31, 2027
Stopped
NCT05129722TerminatedHeart failure with preserved ejection fraction
Difficulties in recruitment at both sites.
NCT01971593TerminatedTetralogy of fallot
Investigator left institution
NCT01708798TerminatedBreast neoplasm
Futility
NCT04300881TerminatedVitreomacular traction
Enrollment
Who is developing eplerenone?
1 company: Boehringer Ingelheim.
- Companies
- Boehringer IngelheimPhase 1diabetic nephropathies
Trial sponsors
Company5 trialsPhase 41,943 people
Company2 trialsPhase 4292 people
Company2 trialsPhase 4282 people
Institut De Recherches Internationales Servier IRIS
Company1 trialPhase 3275 people
Company1 trialPhase 162 people
4 trialsPhase 4488 people
National Institute of Cardiology, Warsaw, Poland
1 trialPhase 42,500 people
1 trialPhase 4172 people
Funding
1 grant since 2026National Heart, Lung, and Blood Institute$773K